Vasantha K Jotwani1,2, Alexandra K Lee3, Michelle M Estrella4,3, Ronit Katz5, Pranav S Garimella6, Rakesh Malhotra6,7, Dena E Rifkin6,7, Walter Ambrosius8, Barry I Freedman8, Alfred K Cheung9, Kalani L Raphael9, Paul Drawz10, Javier A Neyra11, Suzanne Oparil12, Henry Punzi13, Michael G Shlipak4,3, Joachim H Ix6,7. 1. Department of Medicine, San Francisco VA Medical Health Care System, San Francisco, California, USA, vasantha.jotwani@ucsf.edu. 2. Kidney Health Research Collaborative, San Francisco VA Medical Center and University of California, San Francisco, California, USA, vasantha.jotwani@ucsf.edu. 3. Kidney Health Research Collaborative, San Francisco VA Medical Center and University of California, San Francisco, California, USA. 4. Department of Medicine, San Francisco VA Medical Health Care System, San Francisco, California, USA. 5. Kidney Research Institute, University of Washington, Seattle, Washington, USA. 6. Department of Medicine, University of California, San Diego, California, USA. 7. Veterans Affairs San Diego Healthcare System, San Diego, California, USA. 8. Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 9. Department of Medicine, University of Utah, Salt Lake City, Utah, USA. 10. Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA. 11. Department of Medicine, University of Kentucky, Lexington, Kentucky, USA. 12. Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. 13. Punzi Medical Center, Trinity Hypertension Research Institute, Carollton, Texas, USA.
Abstract
BACKGROUND: Kidney tubulointerstitial fibrosis on biopsy is a strong predictor of chronic kidney disease (CKD) progression, and CKD is associated with elevated risk of cardiovascular disease (CVD). Tubular health is poorly quantified by traditional kidney function measures, including estimated glomerular filtration rate (eGFR) and albuminuria. We hypothesized that urinary biomarkers of tubular injury, inflammation, and repair would be associated with higher risk of CVD and mortality in persons with CKD. METHODS: We measured urinary concentrations of interleukin-18 (IL-18), kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and chitinase-3-like protein-1 (YKL-40) at baseline among 2,377 participants of the Systolic Blood Pressure Intervention Trial who had an eGFR < 60 mL/min/1.73 m2. We used Cox proportional hazards models to evaluate biomarker associations with CVD events and all-cause mortality. RESULTS: At baseline, the mean age of participants was 72 ± 9 years, and eGFR was 48 ± 11 mL/min/1.73 m2. Over a median follow-up of 3.8 years, 305 CVD events (3.6% per year) and 233 all-cause deaths (2.6% per year) occurred. After multivariable adjustment including eGFR, albuminuria, and urinary creatinine, none of the biomarkers showed statistically significant associations with CVD risk. Urinary IL-18 (hazard ratio [HR] per 2-fold higher value, 1.14; 95% CI 1.01-1.29) and YKL-40 (HR per 2-fold higher value, 1.08; 95% CI 1.02-1.14) concentrations were each incrementally associated with higher mortality risk. Associations were similar when stratified by randomized blood pressure arm. CONCLUSIONS: Among hypertensive trial participants with CKD, higher urinary IL-18 and YKL-40 were associated with higher risk of mortality, but not CVD.
BACKGROUND: Kidney tubulointerstitial fibrosis on biopsy is a strong predictor of chronic kidney disease (CKD) progression, and CKD is associated with elevated risk of cardiovascular disease (CVD). Tubular health is poorly quantified by traditional kidney function measures, including estimated glomerular filtration rate (eGFR) and albuminuria. We hypothesized that urinary biomarkers of tubular injury, inflammation, and repair would be associated with higher risk of CVD and mortality in persons with CKD. METHODS: We measured urinary concentrations of interleukin-18 (IL-18), kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and chitinase-3-like protein-1 (YKL-40) at baseline among 2,377 participants of the Systolic Blood Pressure Intervention Trial who had an eGFR < 60 mL/min/1.73 m2. We used Cox proportional hazards models to evaluate biomarker associations with CVD events and all-cause mortality. RESULTS: At baseline, the mean age of participants was 72 ± 9 years, and eGFR was 48 ± 11 mL/min/1.73 m2. Over a median follow-up of 3.8 years, 305 CVD events (3.6% per year) and 233 all-cause deaths (2.6% per year) occurred. After multivariable adjustment including eGFR, albuminuria, and urinary creatinine, none of the biomarkers showed statistically significant associations with CVD risk. Urinary IL-18 (hazard ratio [HR] per 2-fold higher value, 1.14; 95% CI 1.01-1.29) and YKL-40 (HR per 2-fold higher value, 1.08; 95% CI 1.02-1.14) concentrations were each incrementally associated with higher mortality risk. Associations were similar when stratified by randomized blood pressure arm. CONCLUSIONS: Among hypertensive trial participants with CKD, higher urinary IL-18 and YKL-40 were associated with higher risk of mortality, but not CVD.
Authors: Insa M Schmidt; Isaac E Hall; Sujata Kale; Sik Lee; Chuan-Hua He; Yashang Lee; Geoffrey L Chupp; Gilbert W Moeckel; Chun Geun Lee; Jack A Elias; Chirag R Parikh; Lloyd G Cantley Journal: J Am Soc Nephrol Date: 2013-01-04 Impact factor: 10.121
Authors: M Park; R Katz; M G Shlipak; D Weiner; R Tracy; V Jotwani; J Hughes-Austin; F Gabbai; C Y Hsu; M Pfeffer; N Bansal; A Bostom; O Gutierrez; M Sarnak; A Levey; J H Ix Journal: Am J Transplant Date: 2017-04-26 Impact factor: 8.086
Authors: Chi-yuan Hsu; Glenn M Chertow; Charles E McCulloch; Dongjie Fan; Juan D Ordoñez; Alan S Go Journal: Clin J Am Soc Nephrol Date: 2009-04-30 Impact factor: 8.237
Authors: Girish N Nadkarni; Veena Rao; Faramarz Ismail-Beigi; Vivian A Fonseca; Sudhir V Shah; Michael S Simonson; Lloyd Cantley; Prasad Devarajan; Chirag R Parikh; Steven G Coca Journal: Clin J Am Soc Nephrol Date: 2016-05-17 Impact factor: 8.237
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Mark J Sarnak; Ronit Katz; Anne Newman; Tamara Harris; Carmen A Peralta; Prasad Devarajan; Michael R Bennett; Linda Fried; Joachim H Ix; Suzanne Satterfield; Eleanor M Simonsick; Chirag R Parikh; Michael G Shlipak Journal: J Am Soc Nephrol Date: 2014-02-07 Impact factor: 10.121
Authors: Chirag R Parikh; Alkesh Jani; Vyacheslav Y Melnikov; Sarah Faubel; Charles L Edelstein Journal: Am J Kidney Dis Date: 2004-03 Impact factor: 8.860
Authors: Anthony N Muiru; Rebecca Scherzer; Simon B Ascher; Vasantha Jotwani; Carl Grunfeld; Judy Shigenaga; Kimberly A Spaulding; Derek K Ng; Deborah Gustafson; Amanda B Spence; Anjali Sharma; Mardge H Cohen; Chirag R Parikh; Joachim H Ix; Michelle M Estrella; Michael G Shlipak Journal: BMC Nephrol Date: 2021-08-30 Impact factor: 2.585
Authors: Alexandra K Lee; Ronit Katz; Vasantha Jotwani; Pranav S Garimella; Walter T Ambrosius; Alfred K Cheung; Lisa H Gren; Javier A Neyra; Henry Punzi; Kalani L Raphael; Michael G Shlipak; Joachim H Ix Journal: Hypertension Date: 2019-08-05 Impact factor: 10.190